Why thrombin PAR1 receptors are important to the cardiac surgical patient.
Targeting of the high-affinity thrombin receptor protease-activated receptor-1 (PAR1) on platelets represents an exciting strategy to curb the pro-thrombotic complications of cardiac surgery without interfering with the hemostatic benefits of thrombin in the coagulation cascade. The first dedicated PAR1 antagonist to complete safety trials this year has justified expectations, showing no increased risk of bleeding when added to standard anti-platelet therapy but halving major adverse cardiovascular events after percutaneous coronary intervention. In the setting of cardiothoracic surgery with cardiopulmonary bypass, an FDA-approved drug already exists with anti-PAR1 properties: aprotinin has been shown to inhibit thrombin-induced platelet activation in vitro and clinically, through sparing of PAR1 receptor cleavage and activation. Because aprotinin also exerts anti-fibrinolytic effects through blockade of plasmin, this indicates a subtle clinical mechanism of action that is simultaneously anti-thrombotic yet hemostatic. PAR1 antagonists would also be expected to exert anti-inflammatory properties through targeting of PAR1 on endothelium, and this principle has been validated in vitro for aprotinin and newer peptidomimetric antagonists. PAR1 antagonism is likely to remain an active and exciting area of research in cardiac surgery, with newer generations of PAR1 antagonists and recombinant aprotinin variants entering clinical development.
Landis
Clive
C
Edmund Cohen Laboratory for Vascular Research, Chronic Disease Research Centre, UWI Bridgetown, Barbados. clandis@uwichill.edu.bb
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D007611:Aprotinin; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods; D004727:Endothelium; D006801:Humans; D008074:Lipoproteins / Q000627:therapeutic use*; D044462:Receptors, Proteinase-Activated / Q000037:antagonists & inhibitors*; D013903:Thoracic Surgery / Q000379:methods*; D013917:Thrombin; D010975:Platelet Aggregation Inhibitors
D000933:Antifibrinolytic Agents; D008074:Lipoproteins; D044462:Receptors, Proteinase-Activated; C051928:lipoprotein-associated coagulation inhibitor; D007611:Aprotinin; D013917:Thrombin; D010975:Platelet Aggregation Inhibitors